Core Viewpoint - China Dongfang (01763.HK) reported a revenue of RMB 2.858 billion for the six months ending June 30, 2025, representing a year-on-year increase of 2% [1] Financial Performance - Gross profit amounted to RMB 1.460 billion, showing a slight decrease of 0.3% year-on-year [1] - Profit attributable to equity shareholders was RMB 172 million, reflecting an increase of 11.3% year-on-year [1] - Basic earnings per share were RMB 0.54 [1] Margin Analysis - The gross margin decreased from 52.1% to 51.1% [1] - The decline in gross profit and gross margin was primarily due to a reduction in revenue from nuclear medicine, while other business segments with higher revenue growth had lower gross margins, which negatively impacted the overall gross margin [1]
中国同辐(01763.HK)：上半年权益股东应占利润1.72亿元 同比增加11.3%